As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Carrion, Ricardo
The purpose of this study will be to evaluate the immunogenicity and protective efficacy of pGX9501 (INO-4800) at a 0.5mg and 1 mg dose in the Rhesus macaque model of SARS-CoV-2 challenge.						
The University of Texas at San Antonio is an emerging Tier One research institution with nearly 29,000 students.
Principal Investigator(s)
Ye, JingYong
Funded by
UTSA VPR Office
In the U.S. alone, 2.8 million people sustain a traumatic brain injury (TBI) each year and seek medical care.1,2 However, there are no FDA approved therapies for effective treatment of TBI (or concussion) patients. Current medications are limited to only reducing secondary damage to the brain following TBI, such as using diuretics to reduce the pressure inside the brain by increasing urine output.
